|
|
Volumn 6, Issue 3, 2009, Pages 123-
|
|
Targeting EGFR in head and neck cancer: A decade of progress
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CETUXIMAB;
CISPLATIN;
EPIDERMAL GROWTH FACTOR RECEPTOR;
FLUOROURACIL;
K RAS PROTEIN;
MONOCLONAL ANTIBODY;
PLATINUM COMPLEX;
TRASTUZUMAB;
PLATINUM;
BREAST CANCER;
CANCER SURVIVAL;
CLINICAL TRIAL;
COLORECTAL CANCER;
COMBINATION CHEMOTHERAPY;
DRUG COST;
DRUG EFFICACY;
DRUG PROTEIN BINDING;
DRUG RESPONSE;
DRUG TARGETING;
EDITORIAL;
HEAD AND NECK CANCER;
HUMAN;
METASTASIS;
PRIORITY JOURNAL;
RECURRENT CANCER;
SQUAMOUS CELL CARCINOMA;
SURVIVAL TIME;
CANCER RECURRENCE;
CROSS RESISTANCE;
OVERALL SURVIVAL;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CISPLATIN;
CLINICAL TRIALS AS TOPIC;
FLUOROURACIL;
HEAD AND NECK NEOPLASMS;
HUMANS;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
TREATMENT OUTCOME;
|
|
EID: 73949095988
PISSN: 17434254
EISSN: 17434262
Source Type: Journal
DOI: 10.1038/ncponc1328 Document Type: Editorial |
|
Times cited : (5)
|
|
References (0)
|
